Company Overview

Fortive Corporation was incorporated in 2015 and is headquartered in Everett, Washington. Fortive innovates essential technologies to keep our world safe and productive. The company's strategic segments – Intelligent Operating Solutions and Advanced Healthcare Solutions – include iconic inventor brands with leading positions in their respective markets. Fortive's businesses design, develop, manufacture, and market products, software, and services, building on leading brand names, innovative technologies, and strong market positions. Fortive employs a team of more than 10,000 research and development, manufacturing, sales, distribution, service, and administrative team members in approximately 50 countries around the world.

Business Segments

Fortive operates primarily through two strategic business segments:

- Intelligent Operating Solutions: This segment markets its products and services under well-recognized brand names such as ACCRUENT, FLUKE, GORDIAN, INDUSTRIAL SCIENTIFIC, INTELEX, PRUFTECHNIK, and SERVICECHANNEL.

- Advanced Healthcare Solutions: This segment provides critical workflow solutions including instrument sterilization, instrument tracking, design and manufacture of cell therapy equipment, biomedical test tools, radiation detection and safety monitoring, and end-to-end clinical productivity software and solutions under brands like ASP, CENSIS, CENSITRAC, EVOTECH, FLUKE BIOMEDICAL, INVETECH, LANDAUER, PROVATION, RAYSAFE, and STERRAD.

Fortive Business System

With a culture rooted in continuous improvement, the core of Fortive's operating model is the Fortive Business System (FBS). FBS serves as the cultural foundation that drives innovation and growth, ensuring the delivery of industry-leading solutions for customers. It is the common thread that connects and empowers all of Fortive's businesses.

Financial Performance and Market Position

Fortive Corporation's financial performance reflects its strategic evolution and operational efficiency. As of June 27, 2025, the company reported revenues of $1.02 billion for Q2 2025, a slight decline of 0.4% year over year, though it exceeded the Zacks Consensus Estimate. Adjusted earnings per share (EPS) for the quarter were 58 cents, marking a 3.6% increase year over year, despite missing the Zacks Consensus Estimate.

For the full year 2024, Fortive achieved revenues of $6.23 billion, a 3% increase year-over-year, including 1% core revenue growth. Net earnings for the full year were $833 million, with adjusted net earnings reported at $1.37 billion. The company maintains a significant market capitalization of approximately $16.52 billion, though it experienced a slight decrease of -1.34% in market cap over the last week.

Key Financial Metrics

- Q2 2025 Performance: Revenues of $1.02 billion, Adjusted EPS of $0.58

- Full Year 2024 Performance: Revenues of $6.23 billion, Net Earnings of $833 million, Adjusted Net Earnings of $1.37 billion

- Trailing 12 Months (TTM) Performance: Revenue of $6.15 billion, Profit of $768.90 million, EPS of $2.22

- Cash Position: $1.83 billion in cash and $4.98 billion in debt, resulting in a net cash position of -$3.14 billion (-$9.29 per share).

- Dividend: Annual dividend of $0.32 per share, yielding 0.68%.

Business Operations and Corporate Transformation

Fortive's operations span approximately 50 countries, supported by a dedicated team of over 10,000 professionals. The company recently underwent a major corporate transformation with the separation of its former Precision Technologies segment.

On June 28, 2025, Fortive completed the spin-off of its Precision Technologies businesses into a new, independent publicly traded company named Ralliant Corporation. This separation was executed through a pro-rata distribution of Ralliant's common stock to Fortive shareholders. This strategic move allows Fortive to sharpen its focus on its core segments: Intelligent Operating Solutions and Advanced Healthcare Solutions.

"The second quarter of 2025 was pivotal for Fortive," stated Olumide Soroye, President and CEO. "We completed our spin-off of Ralliant and launched a new chapter at Fortive with a clear value creation plan to accelerate profitable growth and enhance shareholder returns."

Stock Performance Metrics

Valuation Metrics

- Trailing PE Ratio: 21.24

- Forward PE Ratio: 17.67

- PEG Ratio: 2.81

- EV/EBITDA Ratio: 12.15

- EV/FCF Ratio: 13.80

- EBITDA: $1.68 Billion USD

- EBITDA Margin: 27.61%

Stock Price Performance

- All-Time High: $65.62 (March 22, 2024)

- All-Time Low: $23.50 (March 18, 2020)

- 52-Week Performance: The stock price has decreased by -8.44% over the last 52 weeks.

Risk Metrics

- Beta: 1.07 (indicating price volatility similar to the market average)

- Current Ratio: 0.98

- Debt / Equity Ratio: 0.48

- Return on Equity (ROE): 7.36%

- Return on Invested Capital (ROIC): 4.32%

Future Outlook

For the full year 2025, Fortive anticipates adjusted diluted net earnings per share to be in the range of $2.50 to $2.60. Following the Ralliant spin-off, Fortive is strategically positioned to concentrate its efforts on the Intelligent Operating Solutions and Advanced Healthcare Solutions segments. The company aims to leverage the Fortive Business System to drive sustainable growth and achieve operational excellence.